< Back to latest news & events

News

New Practice at the EPO: Divisional Applications and Sequence Listings

November 2023

Safeguard measure: Excess page fees on ST.25 sequence listings included as part of a divisional application to be waived by the EPO.

Following the implementation of WIPO Sequence standard ST.26, the EPO has required that new divisional applications filed on or after 1 July 2022 require a sequence listing in the ST.26 format, even when the parent application contained an ST.25 standard compliant sequence listing. This practice has been met with concern from practitioners regarding the risk of added subject matter.

To address the concerns around the risk of adding or losing subject matter, the EPO has announced a new safeguard measure. The safeguard measure permits applicants to file the parent application’s ST.25 sequence listing in PDF format as part of the divisional application. Importantly, the ST.25 pages included as a safeguard are excluded from the page fee calculation. Alternatively, the divisional application may be filed by reference to the parent application. In doing so, applicants have the guarantee that the ST.25 sequence listing, which is part of the application, does not contain any additional subject-matter.  In any event, an ST.26 compliant sequence listing will still also need to be filed.

Page fees already paid for pages of sequence listings not complying with WIPO Standard ST.26 will not be refunded.

Full details are expected to be published in the November issue of the Official Journal.

Latest updates

Agritech Thymes: The Bite of Implied Consent: Lessons from the Pink Lady Case

Can the supply of a plant variety without clear and defined restrictions on its use be an implicit consent to commercialise it? This case centres on the evidence required to …

Read article

IAM Global Leaders 2026

HGF is proud to announce that we have 3 partners listed as an IAM Global Leader 2026. To qualify for inclusion in the IAM Global Leaders, individuals must be ranked …

Read article

The Bite of Implied Consent: Lessons from the Pink Lady Case

A recent European Union court decision considers the issue of implied consent to commercialise a plant variety, and whether the evidence meets the threshold of “serious doubts” of the validity …

Read article
Event - 5th November 2025

HGF are Gold Sponsors of IAM Live: Navigating the UPC 2025

We’re excited to share that HGF is a Gold Sponsor of IAM Live: Navigating the UPC 2025, taking place on the 5th November at the Marriott Opera Ambassador Hotel in …

Event details

HGF ranked band 1 in Chambers and Partners UK 2026

The Chambers and Partners UK 2026 Guide is now live and HGF has one again been highly ranked as a firm, with several recognised individuals across multiple regions. HGF is …

Read article

How France's investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Read article
Event - 14th October 2025

The Future of Protein Production Amsterdam 2025

HGF are proud to be sponsoring the Future of Protein Production Amsterdam 2025, the leading global event bringing together innovators across fermentation, cultivated and plant-based proteins. Date: 29-30th October 2025  …

Event details

A Turning Point for AI Patent Eligibility?

Director Squires Vacates PTAB § 101 Rejection in DeepMind Case In a notable early move as Under Secretary of Commerce and USPTO Director, John Squires has vacated a Patent Trial …

Read article